Four-Gene Blood Test Rules Out Bacterial Lung Infection

Misclassification frequently leads to unnecessary antibiotic use, higher healthcare costs, and increased antimicrobial resistance. Now, a new four-gene blood test offers a precise and rapid way to rule out bacterial LRTIs, enabling clinicians to make more accurate treatment decisions.

Researchers at the University of Rochester (Rochester, NY, USA) have developed a molecular diagnostic tool that evaluates the host immune response rather than searching directly for pathogens. Their transcriptomic approach identifies a unique pattern of gene expression that reliably differentiates bacterial from viral infections, providing a powerful complement to traditional diagnostic methods.

Using high-throughput RNA sequencing, the team examined hundreds of adults presenting with LRTI-like symptoms. Thousands of transcripts varied between bacterial and viral infections, but researchers eventually distilled these into a highly accurate four-gene signature optimized for clinical use. One gene strongly reflects bacterial recognition pathways, while the remaining three sharpen the test’s overall discriminatory power. This minimal panel enables rapid and cost-effective testing suitable for routine workflows.

The diagnostic accuracy has major clinical implications. By confidently ruling out bacterial infection, clinicians can withhold antibiotics when they are not needed, preventing unnecessary exposure and slowing the rise of antibiotic resistance. At the same time, patients who do have bacterial disease can be identified more appropriately, improving treatment prioritization and resource allocation.

The test requires only a blood sample, making it easy to deploy in emergency departments, outpatient clinics, and settings with limited laboratory infrastructure. With further development, the method could be adapted for point-of-care testing to support timely decision-making even in remote or resource-restricted environments.

In addition to its clinical utility, the study, published in Nature Communications, also highlights key differences in host immune pathways activated by bacterial versus viral infections, offering deeper insight into the biology of infectious disease. Researchers emphasize that while the four-gene signature enhances diagnostic precision, it must be interpreted alongside clinical context to guide care appropriately.

Future work will involve validating the assay across diverse populations and healthcare systems and moving toward regulatory approval and commercial development. If widely adopted, this diagnostic could transform respiratory infection management by aligning treatment with true underlying pathology and helping preserve antibiotic effectiveness worldwide.

Related Links:
University of Rochester